Lumigan, Bimatoprost Newswire

Lumigan, Bimatoprost Newswire

Comprehensive Real-Time News Feed for Lumigan, Bimatoprost (generic).

Results 1 - 14 of 14 in Lumigan, Bimatoprost (generic)

  1. PAP: New Concerns for Prostaglandin UseRead the original story w/Photo

    Monday | Review of Ophthalmology

    Prostaglandin analogues have become a mainstay of glaucoma treatment, for good reason; they're quite effective at lowering intraocular pressure and don't require multiple applications each day. Until recently, it seemed like the downsides of this class of drug were minimal, making it a good choice for many patients.

    Comment?

  2. Industry FocusRead the original story w/Photo

    Jun 28, 2017 | Contact Lens Spectrum

    Our focus this month is on Allergan, plc, a global pharmaceutical company headquartered in Dublin. I recently had the pleasure to speak with Herman Cukier, senior vice president of US Eye Care.

    Comment?

  3. Recent Analysts' Ratings Updates for Aerie PharmaceuticalsRead the original story w/Photo

    Jun 5, 2017 | AmericanBankingNews.com

    They now have a "buy" rating on the stock. 5/25/2017 - Aerie Pharmaceuticals had its price target raised by analysts at Aegis from $63.00 to $70.00.

    Comment?

  4. Nicox Eyes Partner After First ApprovalRead the original story w/Photo

    Jun 5, 2017 | Seeking Alpha

    After 20 years Nicox finally has an FDA approval under its belt, for the topical antihistamine Zerviate for ocular itching. But it cannot relax just yet - the next challenge will be finding a US partner.

    Comment?

  5. Allergan, Inc. v. Sandoz, Inc.Read the original story w/Photo

    Apr 28, 2017 | jdsupra.com

    Case Name: Allergan, Inc. v. Sandoz, Inc. , Nos. 2016-1085, -1160, 2017 U.S. App.

    Comment?

  6. Aerie Pharmaceuticals' (AERI) Buy Rating Reaffirmed at AegisRead the original story w/Photo

    Apr 28, 2017 | IntersportsWire

    "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us.

    Comment?

  7. Aerie Pharmaceuticals Inc (AERI) Receives "Buy" Rating from AegisRead the original story w/Photo

    Apr 14, 2017 | IntersportsWire

    The firm currently has a $63.00 price objective on the stock. "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event.

    Comment?

  8. Bimatoprost Ophthalmic Solution from Medx4u : for Eyelashes Longer than EverRead the original story w/Photo

    Apr 11, 2017 | PR Log

    Many of us must be thinking about a second chance to get back your eyelash. Is it providing a second life to your dropped out eyelash possible? Latisse is one such eyelash development serum that has shown its success.

    Comment?

  9. Medx4u a user Friendly Online Drugstore Offers Bimatoprost at Low cost Read the original story w/Photo

    Mar 20, 2017 | PR Log

    Medx4u.com is one of the popular drugstores that are introduced in the line of online pharmacy market. The main objective of the invention of Medx4u.com is to provide comfort, ease, complete information of the product, provide medicine at low cost.

    Comment?

  10. Beauty boosters: Medications with cosmetic benefitsRead the original story w/Photo

    Mar 15, 2017 | The Daily Democrat

    Good genes only go so far in resisting aging. For those who want to up their arsenal of beauty boosters, there is a range of over-the counter and prescription medications available to fight skin redness, wrinkles and other beauty battles.

    Comment?

  11. Medications with cosmetic benefitsRead the original story w/Photo

    Mar 9, 2017 | PhysOrg Weblog

    Good genes only go so far in resisting aging. For those who want to up their arsenal of beauty boosters, there is a range of over-the counter and prescription medications available to fight skin redness, wrinkles and other beauty battles.

    Comment?

  12. Buy Bimatoprost ophthalmic Solution from Medxpower at low cost Read the original story w/Photo

    Mar 7, 2017 | PR Log

    Medxpower.com is one of the well-known online drugstores. Among the top online pharmacies, medxpower.com is the one that is identified globally.

    Comment?

  13. Eyelash Growth Serum: What Works, What Doesn'tRead the original story

    Feb 18, 2017 | Self.com

    Eyelash serums are one of those beauty products that seem too good to be true. Sure, there are plenty of temporary lash-lengthening options, like .

    Comment?

  14. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II ...Read the original story

    Feb 2, 2017 | BioSpace

    Envisia Therapeutics Releases Interim ENV515 Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of the second cohort of its ENV515 phase 2 trial in patients with glaucoma showing a clinically meaningful reduction in intraocular pressure for the entire 11-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs and in-study topical timolol maleate 0.5% ophthalmic solution .

    Comment?